FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896932075> ?p ?o ?g. }

• W2896932075 endingPage "289" @default.
• W2896932075 startingPage "277" @default.
• W2896932075 abstract "Abstract Purpose: We examined the role of ERBB2-activating mutations in endocrine therapy resistance in estrogen receptor positive (ER+) breast cancer. Experimental Design: ERBB2 mutation frequency was determined from large genomic databases. Isogenic knock-in ERBB2 mutations in ER+ MCF7 cells and xenografts were used to investigate estrogen-independent growth. Structural analysis was used to determine the molecular interaction of HERL755S with HER3. Small molecules and siRNAs were used to inhibit PI3Kα, TORC1, and HER3. Results: Genomic data revealed a higher rate of ERBB2 mutations in metastatic versus primary ER+ tumors. MCF7 cells with isogenically incorporated ERBB2 kinase domain mutations exhibited resistance to estrogen deprivation and to fulvestrant both in vitro and in vivo, despite maintaining inhibition of ERα transcriptional activity. Addition of the irreversible HER2 tyrosine kinase inhibitor neratinib restored sensitivity to fulvestrant. HER2-mutant MCF7 cells expressed higher levels of p-HER3, p-AKT, and p-S6 than cells with wild-type HER2. Structural analysis of the HER2L755S variant implicated a more flexible active state, potentially allowing for enhanced dimerization with HER3. Treatment with a PI3Kα inhibitor, a TORC1 inhibitor or HER3 siRNA, but not a MEK inhibitor, restored sensitivity to fulvestrant and to estrogen deprivation. Inhibition of mutant HER2 or TORC1, when combined with fulvestrant, equipotently inhibited growth of MCF7/ERBB2V777L xenografts, suggesting a role for TORC1 in antiestrogen resistance induced by ERBB2 mutations. Conclusions: ERBB2 mutations hyperactivate the HER3/PI3K/AKT/mTOR axis, leading to antiestrogen resistance in ER+ breast cancer. Dual blockade of the HER2 and ER pathways is required for the treatment of ER+/HER2 mutant breast cancers." @default.
• W2896932075 created "2018-10-26" @default.
• W2896932075 creator A5007997858 @default.
• W2896932075 creator A5014411546 @default.
• W2896932075 creator A5030367169 @default.
• W2896932075 creator A5031345483 @default.
• W2896932075 creator A5032987754 @default.
• W2896932075 creator A5035120516 @default.
• W2896932075 creator A5039591575 @default.
• W2896932075 creator A5043946489 @default.
• W2896932075 creator A5045194333 @default.
• W2896932075 creator A5048271521 @default.
• W2896932075 creator A5051072215 @default.
• W2896932075 creator A5065600356 @default.
• W2896932075 creator A5080831388 @default.
• W2896932075 creator A5083850731 @default.
• W2896932075 creator A5089051936 @default.
• W2896932075 creator A5089382639 @default.
• W2896932075 date "2019-01-01" @default.
• W2896932075 modified "2023-10-18" @default.
• W2896932075 title "Combined Blockade of Activating <i>ERBB2</i> Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer" @default.
• W2896932075 cites W1867948347 @default.
• W2896932075 cites W1964321121 @default.
• W2896932075 cites W1965827393 @default.
• W2896932075 cites W1971267920 @default.
• W2896932075 cites W1985762436 @default.
• W2896932075 cites W1988142400 @default.
• W2896932075 cites W1997579117 @default.
• W2896932075 cites W1998682097 @default.
• W2896932075 cites W2012877952 @default.
• W2896932075 cites W2021145743 @default.
• W2896932075 cites W2022102157 @default.
• W2896932075 cites W2024651005 @default.
• W2896932075 cites W2025005089 @default.
• W2896932075 cites W2028072190 @default.
• W2896932075 cites W2033672070 @default.
• W2896932075 cites W2037690883 @default.
• W2896932075 cites W2038081635 @default.
• W2896932075 cites W2062713892 @default.
• W2896932075 cites W2069526613 @default.
• W2896932075 cites W2089589284 @default.
• W2896932075 cites W2092897704 @default.
• W2896932075 cites W2095659509 @default.
• W2896932075 cites W2102620699 @default.
• W2896932075 cites W2103484524 @default.
• W2896932075 cites W2113762115 @default.
• W2896932075 cites W2117357260 @default.
• W2896932075 cites W2125785648 @default.
• W2896932075 cites W2133051701 @default.
• W2896932075 cites W2137355132 @default.
• W2896932075 cites W2139444209 @default.
• W2896932075 cites W2141232624 @default.
• W2896932075 cites W2148471287 @default.
• W2896932075 cites W2149580316 @default.
• W2896932075 cites W2157884341 @default.
• W2896932075 cites W2158714788 @default.
• W2896932075 cites W2163011383 @default.
• W2896932075 cites W2163250226 @default.
• W2896932075 cites W2168030291 @default.
• W2896932075 cites W2592465655 @default.
• W2896932075 cites W2606611953 @default.
• W2896932075 cites W2726739357 @default.
• W2896932075 cites W2741790413 @default.
• W2896932075 cites W2785610956 @default.
• W2896932075 cites W4239989216 @default.
• W2896932075 cites W779403461 @default.
• W2896932075 doi "https://doi.org/10.1158/1078-0432.ccr-18-1544" @default.
• W2896932075 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6320312" @default.
• W2896932075 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30314968" @default.
• W2896932075 hasPublicationYear "2019" @default.
• W2896932075 type Work @default.
• W2896932075 sameAs 2896932075 @default.
• W2896932075 citedByCount "66" @default.
• W2896932075 countsByYear W28969320752019 @default.
• W2896932075 countsByYear W28969320752020 @default.
• W2896932075 countsByYear W28969320752021 @default.
• W2896932075 countsByYear W28969320752022 @default.
• W2896932075 countsByYear W28969320752023 @default.
• W2896932075 crossrefType "journal-article" @default.
• W2896932075 hasAuthorship W2896932075A5007997858 @default.
• W2896932075 hasAuthorship W2896932075A5014411546 @default.
• W2896932075 hasAuthorship W2896932075A5030367169 @default.
• W2896932075 hasAuthorship W2896932075A5031345483 @default.
• W2896932075 hasAuthorship W2896932075A5032987754 @default.
• W2896932075 hasAuthorship W2896932075A5035120516 @default.
• W2896932075 hasAuthorship W2896932075A5039591575 @default.
• W2896932075 hasAuthorship W2896932075A5043946489 @default.
• W2896932075 hasAuthorship W2896932075A5045194333 @default.
• W2896932075 hasAuthorship W2896932075A5048271521 @default.
• W2896932075 hasAuthorship W2896932075A5051072215 @default.
• W2896932075 hasAuthorship W2896932075A5065600356 @default.
• W2896932075 hasAuthorship W2896932075A5080831388 @default.
• W2896932075 hasAuthorship W2896932075A5083850731 @default.
• W2896932075 hasAuthorship W2896932075A5089051936 @default.
• W2896932075 hasAuthorship W2896932075A5089382639 @default.
• W2896932075 hasBestOaLocation W28969320751 @default.
• W2896932075 hasConcept C104317684 @default.
• W2896932075 hasConcept C121608353 @default.

• next